The Hidden Cost of Non-Adherence: What Chronic Disease Is Really Costing Egypt's Healthcare System
Quick answer
Non-adherence turns manageable chronic disease into avoidable admissions, lost workdays and lost therapy value. Here is how payers and pharma teams can frame the cost — without inventing numbers.
According to the WHO, noncommunicable diseases account for the large majority of deaths in Egypt, and diabetes, hypertension and dyslipidaemia sit at the centre of that burden. The IDF Diabetes Atlas lists Egypt among the countries with the largest number of adults living with diabetes.
Most of the cost of these diseases is not the medicine. It is what happens when the medicine is not taken: emergency visits, admissions, complications and lost productivity.
Where the cost actually lands
| Stakeholder | How non-adherence shows up |
|---|---|
| Insurers & TPAs | Avoidable admissions, emergency visits and complication claims |
| Employers | Absenteeism, presenteeism and rising medical benefit spend |
| Pharma companies | Early discontinuation, lost persistence and weak real-world evidence |
| Patients & families | Out-of-pocket spending, lost income and caregiver time |
Why Egypt-specific data is hard — and how to work with it
Published Egyptian cost-of-illness studies are limited and often hospital-specific. Rather than borrowing headline numbers from other markets, a credible business case uses your own claims data, prescription refill patterns or programme enrolment forecasts, and states its assumptions openly.
- Define the population: therapy, region, payer mix and expected enrolment.
- Choose two or three measurable indicators: refill persistence, follow-up attendance, avoidable admissions.
- Estimate the baseline from your own data, not from global averages.
- Model scenarios — conservative, expected and optimistic — instead of a single promise.
How an integrated PSP can change the equation
A patient support program delivered by a clinical partner adds the human touchpoints that data alone cannot: nurse education at initiation, follow-up calls, home administration where appropriate and escalation to the treating physician. Hospitalia designs these programmes so that every touchpoint is recorded, which builds the operational data needed to evaluate impact over time.
Real-world data as a regional differentiator
Structured, consented programme data — enrolment, persistence, reasons for discontinuation — is scarce in the region. Collected under proper governance and data-protection rules, it can inform medical affairs, market access and payer discussions.
Discuss your therapy, population and assumptions with Hospitalia's patient support team.
Request a PSP proposalFrequently asked questions
What does non-adherence cost Egypt?
There is no single reliable national figure. The costs appear as avoidable admissions, complications, lost productivity and lost therapy value; the best estimate for your programme comes from your own data and stated assumptions.
Can a PSP reduce hospitalisations?
Well-designed programmes aim to, but results depend on therapy, population and design. Outcomes should be measured, not assumed.
Is Hospitalia an insurer or TPA?
No. Hospitalia is a healthcare delivery partner that provides nursing, home care and patient support services for insurers, TPAs, employers and pharma companies.
